Robidoux's reelection comes as biosimilars get a lift from automatic switching policies in British Columbia and Alberta.
Biosimilars Canada, a national trade association representing biosimilar developers and other industry stakeholders, has reelected Michel Robidoux, the president and general manager of Sandoz Canada, to serve as chair of the Biosimilars Canada board.
In a statement announcing his reappointment, Robidoux praised the biosimilar switching policies implemented by British Columbia and Alberta in 2019. These policies require that patients with chronic conditions be transitioned to certain biosimilars under the oversight of their physician. The programs have achieved savings that proponents have said could be reinvested in health care to broaden access not only to biologics but also other therapies and services.
“Biosimilar medicines have an important role in supporting health care sustainability and patient care,” Robidoux said. “The implementation of biosimilar switching policies could save the Canadian health care system hundreds of millions of dollars.” Citing a 2020 report by the Ontario Drug Policy Research Network, the statement said that annual savings of $425.6 million for provincial drug plans is possible in Canada by switching patients from 3 of the top-selling reference biologics: Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab). “A similar magnitude of savings would be available for employer-sponsored benefit plans,” it said.
Biosimilars Canada is affiliated with the European trade group International Generic and Biosimilar Medicines Association and is a division of the Canadian Generic Pharmaceutical Association. The group also reelected Mike Woolcock to serve as vice chair of the board. Woolcock is a senior vice president at Apobiologix. Other companies represented by Biosimilars Canada include Auropharma, Fresenius Kabi, Pharmascience, Taro, Teva, and Viatris.
For an update on biosimilar savings in British Columbia from the perspective of Pacific Blue Cross, click here.
Breaking Down Biosimilar Barriers: Payer and PBM Policies
November 13th 2024Part 2 of this series for Global Biosimilars Week dives into the complexities of payer and pharmacy benefit manager (PBM) policies, how they impact biosimilar accessibility, and how addressing these issues may look under a second Trump term.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo
November 7th 2024For the first time, Skyrizi (risankizumab-rzaa) has replaced Humira (reference adalimumab) as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.